Search

Displaying results 1261 - 1270 of 6074 in total
  1. Drug

    Cefalotin

    go.drugbank.com/drugs/DB00456
    ApprovedVet approvedWithdrawn

    Cefalotin is a cephalosporin antibiotic.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  2. Drug

    Odesivimab

    go.drugbank.com/drugs/DB15900
    ApprovedInvestigational

    Ebola virus (EBOV) remains an important human pathogen within the _Ebolavirus_ genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%. … [A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection.

    Categories: Treatments for Ebola Virus Disease
  3. Drug

    Meclofenamic acid

    go.drugbank.com/drugs/DB00939
    ApprovedInvestigationalVet approved

    A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.

    Categories: Topical Products for Joint and Muscular Pain, Antiinflammatory Preparations, Non-Steroids for Topical Use
  4. Drug

    Lindane

    go.drugbank.com/drugs/DB00431
    ApprovedWithdrawn

    Lindane is still allowed for pharmaceutical use until 2015. … In Canada, Lindane is not recommmended as a first-line therapy due to reports of resistance, neurotoxicity, and bone marrow suppression, but has been approved by the FDA as a second-line therapy for topical

  5. Drug

    Phenylpropanolamine

    go.drugbank.com/drugs/DB00397
    ApprovedVet approvedWithdrawn

    Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes.

    Categories: Nasal Decongestants for Systemic Use, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  6. Drug

    Efgartigimod alfa

    go.drugbank.com/drugs/DB15270
    ApprovedInvestigational

    Efgartigimod alfa for intravenous use was granted FDA approval on December 17, 2021[L39501] and European Commission approval on August 11, 2022 for use in patients with myasthenia gravis. … [L43190] A formulation for subcutaneous use that combines efgartigimod alfa and hyaluronidase was later approved for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP

  7. Drug

    Magaldrate

    go.drugbank.com/drugs/DB08938
    ApprovedInvestigationalWithdrawn

    Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market.

    Categories: Drugs for Acid Related Disorders
  8. Drug

    Ranolazine

    go.drugbank.com/drugs/DB00243
    ApprovedInvestigational

    [A189234] Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms.

  9. Drug

    Atogepant

    go.drugbank.com/drugs/DB16098
    ApprovedInvestigational

    novel in that it is the first and only oral CGRP antagonist approved for preventative use in migraine. … [L44642] It also received approval for preventive treatment of adult migraine by the EMA in August 2023.

  10. Drug

    Vonoprazan

    go.drugbank.com/drugs/DB11739
    ApprovedInvestigational

    PCABs represent an alternative to proton-pump inhibitors for the treatment of acid-related disorders. … [A253702] In May 2022, the FDA approved the use of vonoprazan in a co-packaged product containing amoxicillin and clarithromycin for the treatment of _H. pylori_ infection.

    Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)